查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600531

生物製藥市場：按產品類型、服務、原料類型、應用分類 - 全球預測 2025-2030

Biopharmaceuticals Market by Product Type, Services, Raw Material Type, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生物製藥市場估值為5,740.4億美元，預計2024年將達到6,271.9億美元，複合年成長率為9.74%，到2030年將達到11.0051億美元。

生物製藥產業包括生物來源藥物和治療方法的研究、開發和製造。該細分市場因其能夠治療癌症和自體免疫疾病等複雜疾病而發揮重要作用。對生物製藥的需求在於其先進的功效和特異性，與傳統藥物相比，副作用更少，並提供個人化的治療選擇。最終用途包括疫苗、單株抗體以及細胞和基因治療，範圍包括醫院、專科診所和研究機構。

主要市場統計
基準年[2023] 5740.4億美元
預測年份 [2024] 6271.9億美元
預測年份 [2030] 1,100,510 百萬美元
複合年成長率（%） 9.74%

市場成長主要由慢性病的增加、技術進步以及研發投資的增加所推動。此外，政府的支持政策和對有效治療方法的需求不斷增加也為產業相關人員創造了重大機會。生物相似藥的開發是一項新的商機，它可以為昂貴的生物製藥提供具有成本效益的替代品。此外，在藥物發現和個人化醫療中使用人工智慧（AI）和機器學習可以縮短上市時間並提高治療效果。

儘管預計將出現強勁成長，但生物製藥市場面臨研發成本高、製造流程複雜和監管要求嚴格等限制。市場進入障礙和智慧財產權問題等挑戰正在阻礙成長和採用。為了解決這些問題，企業正在投資建立夥伴關係和研究合作，以加速研究、簡化製造流程、利用人工智慧創新藥物開發，並考慮開拓具有有利監管環境的新興市場。

業務成長的創新領域包括 CRISPR 等基因編輯技術、新型藥物傳輸系統、疫苗平台的擴展，尤其是 mRNA 技術。這些進步預計將徹底改變治療模式並創造新的收益來源。市場競爭激烈、技術變革迅速、專業化程度高，需要策略敏捷性和持續創新才能保持領先並抓住新機會。

市場動態：揭示快速發展的生物製藥市場的關鍵市場洞察

供需的動態交互作用正在改變生物製藥市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率和目標需求生物製藥
    • 加大疫苗和藥物研發投資
    • 有吸引力的生物製藥報銷政策
  • 市場限制因素
    • 原料供應鏈中斷與藥物開發成本上升
  • 市場機會
    • 生物製藥製造和檢測技術的進步
    • 生技藥品和疫苗製造外包的新趨勢
  • 市場問題
    • 藥品生產的嚴格監管架構和耗時的臨床測試

波特五力：駕馭生物製藥市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解生物製藥市場的外部影響

外部宏觀環境因素在塑造生物製藥市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解生物製藥市場的競爭格局

生物製藥市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣：生物製藥市場供應商績效評估

FPNV定位矩陣是評估生物製藥市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的盛行率和標靶治療的需求 生物製藥
      • 加大疫苗和藥物研發投資
      • 有吸引力的生物製藥報銷政策
    • 抑制因素
      • 原料供應鏈中斷及藥物開發高成本
    • 機會
      • 生物製藥製造和檢測技術的進步
      • 生技藥品和疫苗製造外包的新趨勢
    • 任務
      • 嚴格的藥品生產法規結構和耗時的臨床測試
  • 市場區隔分析
    • 產品類型：正在進行的舉措，以推動單株抗體領域的創新
    • 服務：需要進行藥典和多藥典實驗室檢查，以確保合規性
    • 原料類型：致力於開發強大的API用於疾病的診斷、治療和緩解
    • 應用：需要透過改變生活方式來治療心血管疾病
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化

第6章生物製藥市場：依產品類型

  • 介紹
  • 單株抗體
  • 精製蛋白
  • 重組生長因子
  • 重組激素
  • 重組蛋白
  • 合成免疫調節劑
  • 疫苗

第7章生物製藥市場：依服務分類

  • 介紹
  • 藥典和多藥典實驗室測試
  • 客自訂測試或客戶特定檢查
  • 臨床檢查

第8章生物製藥市場：依原料類型

  • 介紹
  • 活性藥物成分
  • 配方添加物

第9章生物製藥市場：依應用分類

  • 介紹
  • 自體免疫疾病
  • 心血管疾病
  • 荷爾蒙失調
  • 免疫學
  • 發炎和感染疾病
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤學

第10章美洲生物藥學市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生物製藥市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的生物製藥市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 阿斯特捷利康將以 11 億美元收購呼吸道融合病毒（RSV）疫苗開發商 Icosavax
    • 阿茲海默症治療藥物「LEQEMBI靜脈靜脈注射（Lecanemab）」12月20日在日本上市
    • 美國衛生與公眾服務部 (HHS) 宣布與再生元 (Regeneron) 合作開發救生單株抗體的詳細資訊

公司名單

  • AbbVie Inc.
  • Avidea Technologies
  • Bayer AG
  • Thermo Fisher Scientific Inc.
  • Ferring Pharmaceuticals
  • Abbott Laboratories
  • LG Chem Life Sciences Innovation Center, Inc.
  • Ipsen Pharma
  • Novo Nordisk A/S
  • Amgen Inc.
  • BTL BIoTechno Labs Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • bioMerieux SA
  • Nordic BioSite
  • GlaxoSmithKline PLC
  • Novartis AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Abgenex
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • Takeda Pharmaceutical Company Limited
  • Bio-Techne Corporation
  • Biogen Inc.
Product Code: MRR-434CCDA05130

The Biopharmaceuticals Market was valued at USD 574.04 billion in 2023, expected to reach USD 627.19 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 1,100.51 billion by 2030.

The biopharmaceutical industry encompasses the research, development, and manufacturing of biological drugs and therapies derived from living organisms. This sector plays a critical role due to its capacity to treat complex diseases like cancer and autoimmune disorders. The necessity of biopharmaceuticals lies in their advanced efficacy and specificity, offering fewer side effects and personalized treatment options compared to traditional pharmaceuticals. Applications include vaccines, monoclonal antibodies, and cell and gene therapies, with end use spanning hospitals, specialty clinics, and research institutes.

KEY MARKET STATISTICS
Base Year [2023] USD 574.04 billion
Estimated Year [2024] USD 627.19 billion
Forecast Year [2030] USD 1,100.51 billion
CAGR (%) 9.74%

Market growth is primarily driven by the increasing prevalence of chronic diseases, technological advancements, and heightened investments in R&D. Additionally, supportive government policies and growing demand for effective therapies create substantial opportunities for industry players. One emerging opportunity lies in the development of biosimilars, which can offer cost-effective alternatives to expensive biopharmaceuticals. Another potential area is leveraging artificial intelligence (AI) and machine learning for drug discovery and personalized medicine, which can reduce time-to-market and enhance treatment efficacy.

Despite robust growth prospects, the biopharma market faces limitations, including high R&D costs, complex manufacturing processes, and stringent regulatory requirements. Challenges like market access barriers and intellectual property issues further hinder growth and adoption. To address these, firms should consider investing in partnerships and collaborations that can accelerate research and streamline production processes, utilize AI to innovate drug development, and explore emerging markets with favorable regulatory scenarios.

Innovative areas for business growth include gene editing technologies like CRISPR, novel drug delivery systems, and expanding vaccine platforms, especially mRNA technology. These advancements promise to revolutionize treatment paradigms and create new revenue streams. The market is characterized by intense competition, rapid technological shifts, and a high degree of specialization, necessitating strategic agility and continuous innovation to maintain leadership and capture emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceuticals Market

The Biopharmaceuticals Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
    • Rising Investments in Vaccine and Drugs Development
    • Attractive Reimbursement Policies for Biopharmaceuticals
  • Market Restraints
    • Raw Material Supply Chain Disruptions and High Cost of Drug Development
  • Market Opportunities
    • Advancements in Biopharmaceutical Manufacturing and Testing Technologies
    • Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
  • Market Challenges
    • Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceuticals Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceuticals Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceuticals Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceuticals Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceuticals Market

A detailed market share analysis in the Biopharmaceuticals Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceuticals Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceuticals Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Avidea Technologies, Bayer AG, Thermo Fisher Scientific Inc., Ferring Pharmaceuticals, Abbott Laboratories, LG Chem Life Sciences Innovation Center, Inc., Ipsen Pharma, Novo Nordisk A/S, Amgen Inc., BTL Biotechno Labs Pvt. Ltd., Johnson & Johnson Services, Inc., Pfizer, Inc., bioMerieux SA, Nordic BioSite, GlaxoSmithKline PLC, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi S.A., Abgenex, AstraZeneca PLC, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Bio-Techne Corporation, and Biogen Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Monoclonal Antibodies, Purified Proteins, Recombinant Growth Factors, Recombinant Hormone, Recombinant Proteins, Synthetic Immunomodulators, and Vaccines.
  • Based on Services, market is studied across Compendial & Multi Compendial Laboratory Testing, Custom Testing or Customer Proprietary Testing, and Laboratory Testing.
  • Based on Raw Material Type, market is studied across Active Pharmaceutical Ingredient and Formulation Excipients.
  • Based on Application, market is studied across Autoimmune Disorders, Cardiovascular Diseases, Hormonal Disorders, Immunology, Inflammatory & Infectious Diseases, Metabolic Disorders, Neurological Diseases, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
      • 5.1.1.2. Rising Investments in Vaccine and Drugs Development
      • 5.1.1.3. Attractive Reimbursement Policies for Biopharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. Raw Material Supply Chain Disruptions and High Cost of Drug Development
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Biopharmaceutical Manufacturing and Testing Technologies
      • 5.1.3.2. Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Ongoing R&D initiatives to promote innovations in the field of monoclonal antibodies
    • 5.2.2. Services: Need for compendial & multi compendial laboratory testing to ensure compliance with regulations
    • 5.2.3. Raw Material Type: Efforts to develop potent APIs to diagnose, cure, or mitigate disease conditions
    • 5.2.4. Application: Changes in lifestyles leading to the need for treatment strategies for cardiovascular diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Biopharmaceuticals Market, by Product Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Purified Proteins
  • 6.4. Recombinant Growth Factors
  • 6.5. Recombinant Hormone
  • 6.6. Recombinant Proteins
  • 6.7. Synthetic Immunomodulators
  • 6.8. Vaccines

7. Biopharmaceuticals Market, by Services

  • 7.1. Introduction
  • 7.2. Compendial & Multi Compendial Laboratory Testing
  • 7.3. Custom Testing or Customer Proprietary Testing
  • 7.4. Laboratory Testing

8. Biopharmaceuticals Market, by Raw Material Type

  • 8.1. Introduction
  • 8.2. Active Pharmaceutical Ingredient
  • 8.3. Formulation Excipients

9. Biopharmaceuticals Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Disorders
  • 9.3. Cardiovascular Diseases
  • 9.4. Hormonal Disorders
  • 9.5. Immunology
  • 9.6. Inflammatory & Infectious Diseases
  • 9.7. Metabolic Disorders
  • 9.8. Neurological Diseases
  • 9.9. Oncology

10. Americas Biopharmaceuticals Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biopharmaceuticals Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biopharmaceuticals Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
    • 13.3.2. LEQEMBI Intravenous Infusion (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
    • 13.3.3. HHS Announces Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Avidea Technologies
  • 3. Bayer AG
  • 4. Thermo Fisher Scientific Inc.
  • 5. Ferring Pharmaceuticals
  • 6. Abbott Laboratories
  • 7. LG Chem Life Sciences Innovation Center, Inc.
  • 8. Ipsen Pharma
  • 9. Novo Nordisk A/S
  • 10. Amgen Inc.
  • 11. BTL Biotechno Labs Pvt. Ltd.
  • 12. Johnson & Johnson Services, Inc.
  • 13. Pfizer, Inc.
  • 14. bioMerieux SA
  • 15. Nordic BioSite
  • 16. GlaxoSmithKline PLC
  • 17. Novartis AG
  • 18. Eli Lilly and Company
  • 19. Merck & Co., Inc.
  • 20. Bristol-Myers Squibb Company
  • 21. Sanofi S.A.
  • 22. Abgenex
  • 23. AstraZeneca PLC
  • 24. F. Hoffmann-La Roche AG
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Bio-Techne Corporation
  • 27. Biogen Inc.

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOPHARMACEUTICALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOPHARMACEUTICALS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SYNTHETIC IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COMPENDIAL & MULTI COMPENDIAL LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CUSTOM TESTING OR CUSTOMER PROPRIETARY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY FORMULATION EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY & INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 200. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023